Last reviewed · How we verify

Artesunate+Sulfamethoxypyrazine/pyrimethamine

Kenya Medical Research Institute · Phase 3 active Small molecule

Artesunate+Sulfamethoxypyrazine/pyrimethamine is a Antimalarial combination therapy Small molecule drug developed by Kenya Medical Research Institute. It is currently in Phase 3 development for Malaria (Plasmodium falciparum infection). Also known as: Co-arinate FDC.

This combination drug uses artesunate to disrupt malaria parasite metabolism while sulfamethoxypyrazine and pyrimethamine inhibit folate synthesis pathways essential for parasite survival.

This combination drug uses artesunate to disrupt malaria parasite metabolism while sulfamethoxypyrazine and pyrimethamine inhibit folate synthesis pathways essential for parasite survival. Used for Malaria (Plasmodium falciparum infection).

At a glance

Generic nameArtesunate+Sulfamethoxypyrazine/pyrimethamine
Also known asCo-arinate FDC
SponsorKenya Medical Research Institute
Drug classAntimalarial combination therapy
TargetPlasmodium falciparum (multiple targets: artemisinin-induced oxidative stress, dihydrofolate reductase)
ModalitySmall molecule
Therapeutic areaInfectious Disease
PhasePhase 3

Mechanism of action

Artesunate is an artemisinin derivative that generates reactive oxygen species and damages parasite proteins and membranes. Sulfamethoxypyrazine and pyrimethamine are antifolate agents that inhibit dihydrofolate reductase and other enzymes in the folate synthesis pathway, preventing nucleotide production necessary for parasite DNA replication. The combination provides synergistic antimalarial activity through complementary mechanisms.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Artesunate+Sulfamethoxypyrazine/pyrimethamine

What is Artesunate+Sulfamethoxypyrazine/pyrimethamine?

Artesunate+Sulfamethoxypyrazine/pyrimethamine is a Antimalarial combination therapy drug developed by Kenya Medical Research Institute, indicated for Malaria (Plasmodium falciparum infection).

How does Artesunate+Sulfamethoxypyrazine/pyrimethamine work?

This combination drug uses artesunate to disrupt malaria parasite metabolism while sulfamethoxypyrazine and pyrimethamine inhibit folate synthesis pathways essential for parasite survival.

What is Artesunate+Sulfamethoxypyrazine/pyrimethamine used for?

Artesunate+Sulfamethoxypyrazine/pyrimethamine is indicated for Malaria (Plasmodium falciparum infection).

Who makes Artesunate+Sulfamethoxypyrazine/pyrimethamine?

Artesunate+Sulfamethoxypyrazine/pyrimethamine is developed by Kenya Medical Research Institute (see full Kenya Medical Research Institute pipeline at /company/kenya-medical-research-institute).

Is Artesunate+Sulfamethoxypyrazine/pyrimethamine also known as anything else?

Artesunate+Sulfamethoxypyrazine/pyrimethamine is also known as Co-arinate FDC.

What drug class is Artesunate+Sulfamethoxypyrazine/pyrimethamine in?

Artesunate+Sulfamethoxypyrazine/pyrimethamine belongs to the Antimalarial combination therapy class. See all Antimalarial combination therapy drugs at /class/antimalarial-combination-therapy.

What development phase is Artesunate+Sulfamethoxypyrazine/pyrimethamine in?

Artesunate+Sulfamethoxypyrazine/pyrimethamine is in Phase 3.

What are the side effects of Artesunate+Sulfamethoxypyrazine/pyrimethamine?

Common side effects of Artesunate+Sulfamethoxypyrazine/pyrimethamine include Gastrointestinal disturbances (nausea, vomiting, diarrhea), Headache, Fever, Hematologic effects (anemia, thrombocytopenia), Hepatotoxicity.

What does Artesunate+Sulfamethoxypyrazine/pyrimethamine target?

Artesunate+Sulfamethoxypyrazine/pyrimethamine targets Plasmodium falciparum (multiple targets: artemisinin-induced oxidative stress, dihydrofolate reductase) and is a Antimalarial combination therapy.

Related